Antiphospholipid Antibody Induced by Nivolumab

الملخص EN

Nivolumab is a monoclonal antibody against the programmed death protein 1 and is used for patients with advanced melanoma.

It is associated with potentially immune-related adverse events, including disorders of the skin, GI tract, and the thyroid; these disorders were successfully treated with prednisone and infliximab.

Other immunotherapeutic agents were observed to induce the formation of antiphospholipid antibody (APA) including α-interferon and interleukin-2.

We present a case of APA development after the third dose of nivolumab in a 71-year-old male with advanced melanoma.

The APA was detected after finding a prolonged aPTT; the lupus anticoagulant assay tested positive.

The patient was treated with prednisone but, unfortunately, he expired a few days later.